Device / Combination Product Manager

San Diego · On-site$110k – $135k

About this role

Description

The Device / Combination Product Manager serves as the internal technical leader and subject-matter expert for medical device and drug-device combination product development across Viking Therapeutics’ pipeline. This role partners closely with internal Chemistry, Manufacturing and Controls (CMC), Drug Product, Analytical Development, Quality, Regulatory Affairs, Clinical, and Supply Chain teams, as well as with external device suppliers, contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs), to plan and execute phase-appropriate device and combination product activities from early development through late-stage clinical and pre-commercial readiness. The Device / Combination Product Director will establish and oversee design controls, risk management, human factors, and design verification and validation for the device constituent parts of combination products (such as prefilled syringes, autoinjectors, and pen injectors), and will ensure compliance with applicable combination product and device regulations. The role will contribute device and combination product content to CMC documentation and regulatory submissions across Viking’s portfolio, including the company’s lead GLP-1/GIP dual agonist program (VK2735) and additional metabolic and endocrine disorder pipeline assets. The level of the role will be commensurate with the candidate’s experience and qualifications.

Essential Duties and Responsibilities 

The main responsibilities of this role include:

  • Serve as the internal subject-matter expert and technical lead for medical device and combination product development across Viking’s portfolio, including the device constituent parts of drug-device combination products such as prefilled syringes, autoinjectors, and pen injectors.
  • Establish and maintain design control processes (per 21 CFR 820.30 and ISO 13485) and the Design History File (DHF), including user needs, design inputs and outputs, design reviews, and design verification and validation.
  • Lead device and combination product risk management activities in accordance with ISO 14971, including hazard analysis, design and use FMEAs, and benefit-risk assessment throughout the product lifecycle.
  • Direct human factors and usability engineering programs (per IEC 62366-1 and applicable FDA human factors guidance), including formative and summative studies, use-related risk analysis, and instructions for use.
  • Oversee device and combination product activities at external suppliers, device CMOs, and CDMOs, including design transfer, component qualification, biocompatibility (ISO 10993), and manufacturing and assembly controls.
  • Author and review device and combination product sections of regulatory submissions (INDs, CTAs, NDAs/BLAs) consistent with 21 CFR Part 4 combination product cGMP requirements, and support responses to health authority questions in collaboration with Regulatory Affairs.
  • Define device specifications, essential performance requirements, acceptance criteria, and control strategies; support container-closure, extractables and leachables, and device performance testing in partnership with Drug Product and Analytical Development.
  • Partner cross-functionally with CMC, Drug Product, Quality, Regulatory Affairs, Clinical, and Supply Chain to ensure integrated, phase-appropriate, on-time combination product deliverables.
  • Provide device and combination product updates, risk assessments, and timelines at integrated project team meetings and to executive stakeholders, and help build internal device capability, processes, and governance.
  • Other duties as assigned.

Requirements

Education and Experience

  • B.S. in Biomedical Engineering, Mechanical Engineering, a related engineering field, or a relevant scientific discipline, with 10+ years of medical device and/or combination product development experience in the pharmaceutical, biotech, or medical device industry; or M.S. with 8+ years; or an equivalent combination of education and experience.
  • Title and level (Director vs. Senior Director) will be commensurate with the candidate’s experience and qualifications.

Knowledge and Skills

  • Demonstrated hands-on experience developing drug-device combination products (e.g., prefilled syringes, autoinjectors, pen injectors) from concept through commercialization, including design and integration of the device constituent part.
  • Working knowledge of combination product and device regulations and standards, including 21 CFR Part 4, 21 CFR 820 (Quality System Regulation), ISO 13485, ISO 14971, IEC 62366-1, and ISO 10993.
  • Experience establishing and managing design controls, Design History Files, design verification and validation, and human factors / usability engineering programs.
  • Track record of managing external device suppliers, CMOs, and CDMOs, including design transfer, component qualification, and delivery on time and within budget.
  • Experience authoring device and combination product sections of regulatory submissions and supporting health authority interactions in collaboration with Regulatory Affairs.
  • Experience with parenteral / injectable delivery systems and, ideally, peptide or GLP-1/GIP combination products and associated cold-chain considerations, is a plus.
  • Strong written and verbal communication skills; ability to translate technical device matters into clear documentation and regulatory content, and to influence cross-functional and executive stakeholders.
  • Entrepreneurial mindset with the ability to thrive in a fast-paced, lean biotech environment; strong organizational skills, attention to detail, and the ability to build internal capability while managing multiple priorities and external partners simultaneously.

VIKING THERAPEUTICS

Viking Therapeutics, Inc., is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Viking Therapeutics also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA.

Notice to Agency and Search Firm Representatives

Viking Therapeutics, Inc. is not accepting unsolicited resumes from agencies and/or search firms for this job posting. Resumes submitted to any Viking employee by a third-party agency and/or search firm without a valid written & signed search agreement, and assignment of specific position, will become the sole property of Viking Therapeutics, Inc. No fee will be paid if a candidate is hired for this position as a result of an unsolicited agency or search firm referral.

Salary Description

$110,000.00 - $135,000.00 annual salary

Company at a glance

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).

Founded2012
Team Size51-200 employees
WorkspaceOn-site
IndustryPharmaceutical Manufacturing
Location
San Diego, California, United States

Tired of cold applications?

Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.

Know someone who'd be great for this?